Table 1. Ranking of the Probability of Being the Best Treatment Regimena.
| Treatment regimen | Median rank (95% CrI)b |
|---|---|
| Pembrolizumab, 2 mg/kg, every 3 wk | 1 (1-7) |
| Nivolumab, 3 mg/kg, every 2 wk | 2 (1-6) |
| Pembrolizumab, 10 mg/kg, every 3 wk | 3 (1-7) |
| Ipilimumab, 3 mg/kg, every 3 wk | 4 (1-6) |
| Chemotherapyc | 5 (2-7) |
| Pembrolizumab, 10 mg/kg, every 2 wk | 6 (1-8) |
| Nivolumab, 1 mg/kg, every 3 wk and ipilimumab, 3 mg/kg, every 3 wk | 7 (2-8) |
| Ipilimumab, 10 mg/kg, every 3 wk | 7 (4-8) |
Abbreviation: CrI, credible interval.
We ranked this probability by estimating the median (95% CrIs) of the posterior distribution for the rank of each treatment regimen. Some median ranks across different treatment regimens were the same because rank was an integer. The best treatment regimen was the one with the lowest risk of any immune-related adverse event.
Median rank refers to the median and the 95% CrI refers to the 95% CrI of the posterior distribution for the rank of each treatment regimen.
Immune-related adverse events were the outcomes associated with immune checkpoint inhibitors, not chemotherapy drugs (ie, carboplatin, dacarbazine, and paclitaxel). For patients receiving chemotherapy, the adverse events identified were associated with chemotherapy.